Understanding different types of endometrial cancer
Multiple Classifier Endometrial Cancer
This study looks at different types of endometrial cancer to see if understanding their unique features can help doctors predict outcomes and choose better treatments for patients with early-stage disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT05976113 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the classification of endometrial cancer, which is a heterogeneous group of diseases. It aims to improve the understanding of various molecular subtypes of endometrial cancer, moving beyond the traditional dualistic classification. By incorporating molecular and genetic information, the study seeks to enhance prognosis prediction and treatment guidance for patients with early-stage endometrial cancer. The study will analyze data from patients who have undergone hysterectomy and have had their tumors evaluated both pathologically and molecularly.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a histological diagnosis of early-stage endometrial cancer who have undergone hysterectomy and have had molecular evaluations of their tumors.
Not a fit: Patients with stage IV endometrial cancer or those who have received neoadjuvant therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate prognostic assessments and tailored treatment strategies for patients with endometrial cancer.
How similar studies have performed: Other studies have shown promise in utilizing molecular classifications for cancer prognosis, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria were the following: (i) histological diagnosis of endometrial cancer; (ii) execution of hysterectomy (with or without salpingo-oophorectomy) with or without nodal dissection; (iii) apparent early-stage disease; (iv) conventional pathological evaluation; and (v) molecular/genomic evaluation of the disease (including at least POLE sequencing, MMR protein immunostaining or MSI assessment, p53 immunostaining or TP53 sequencing). Exclusion criteria were: (i) consent withdrawal, (ii) execution of neoadjuvant therapy, and (iii) stage IV disease.
Where this trial is running
Milan
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano — Milan, Italy (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.